Abstract 735P
Background
Testicular germ cell tumors (TGCT) have an excellent prognosis. This study aimed to provide population-based clinical data on cause-specific deaths with detailed treatment information, as such data are scarce.
Methods
From the Cancer Registry of Norway we identified 6167 men with testicular cancer diagnosed 1980-2009, of whom 714 died before 2011. Excluding non-TGCT, clinical or post-mortem diagnoses, 588 were included. Information on Royal Marsden clinical stage (CS), comorbidity, treatment, follow-up and cause of death was obtained from patient journals.
Results
Of 588 deceased patients, 311, 191 and 86 were diagnosed in the 1980s, 90s and 00s, respectively. Most had seminoma (55%), and 48% were concurrent smokers. Median time to death (MTD) of TGCT, treatment complications or other causes was 1.5, 0.4 and 12.1 years, respectively. Of 315 deceased patients with initial CS1, 4% died of relapsed TGCT or treatment complications, while 35% died of non-TGCT cancer. Of 273 deceased patients with initial metastatic TGCT, 149 (55%) died of TCGT or treatment complications. Most had nonseminoma (77%). The primary treatment in these 149 patients was a combination of chemotherapy and surgery in 41%, chemotherapy alone in 33%, radiotherapy alone in 3%, trimodal treatment in 11%, radiotherapy and chemotherapy in 7%, while 4% received no treatment. Of the 149 patients, 95 (64 %) had CS4: pulmonary metastases, non-pulmonary visceral metastases or both were reported in 84, 42 and 34 patients, respectively. According to IGCCCG, 61%, 27% and 4% belonged to the poor, intermediate and good prognosis groups, respectively. Most (58%) died in primary treatment before entering follow-up. Of all 273 patients, 14 % died of non-TGCT cancer.
Conclusions
In this complete three-decade cohort, cause-specific death of TGCT was exceedingly rare in CS1 or good prognosis metastatic disease. TGCT death was rare if patients went into follow-up after primary treatment. Cause-specific mortality was most pronounced in patients receiving chemotherapy following post-chemotherapy surgery, in patients with nonseminoma or with visceral metastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Central Norway Regional Health Authority.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18